Advertisement

Colorectal Cancer: Adjuvant Therapy

  • Kelli Bullard Dunn
  • Judith L. Trudel
Chapter

Abstract

The stage of disease at presentation is the most important predictor of outcome for colon cancer patients. Stage I (T1-2N0M0) disease carries an excellent prognosis of up to 95% 5-year survival rate after resection, and surgical treatment alone is considered sufficient; adjuvant treatment is not indicated.1 Patients with stage II disease (T3-4N0M0) also have excellent 5-year survival, averaging 70–80%, but a subset of high-risk patients have poorer prognosis.1 As such, it has been suggested that some stage II patients may benefit from adjuvant therapy, but the role of treatment in this patient population remains controversial. In contrast, adjuvant treatment repeatedly has been shown to improve survival for stage III (TanyN1-2M0) disease.

Keywords

Colon Cancer Local Recurrence Rectal Cancer Total Mesorectal Excision Local Recurrence Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedGoogle Scholar
  2. 2.
    Jemal A et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52(1):23–47.PubMedGoogle Scholar
  3. 3.
    NCCNetwork. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003;1:40–53.Google Scholar
  4. 4.
    Wolmark N et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30–6.PubMedGoogle Scholar
  5. 5.
    Laurie JA et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7(10):1447–56.PubMedGoogle Scholar
  6. 6.
    Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.PubMedGoogle Scholar
  7. 7.
    Conference NC. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.Google Scholar
  8. 8.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–44.Google Scholar
  9. 9.
    Wolmark N et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11(10):1879–87.PubMedGoogle Scholar
  10. 10.
    O’Connell MJ et al. Prospectively randomized trial of ­postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300.PubMedGoogle Scholar
  11. 11.
    Haller DG, Catalano PJ, MacDonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol. 1998;17:256.Google Scholar
  12. 12.
    Wolmark N et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553–9.PubMedGoogle Scholar
  13. 13.
    Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet. 2000;355(9215):1588–96.Google Scholar
  14. 14.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356–63.Google Scholar
  15. 15.
    Schrag D, Gelfand S, Bach P, et al. Adjuvant chemotherapy for stage II colon cancer: insight from a SEER-Medicare cohort. Proc Am Soc Clin Oncol. 2001;20:488.Google Scholar
  16. 16.
    Mamounas E et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17(5):1349–55.PubMedGoogle Scholar
  17. 17.
    Buyse M, Piedbois P. Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001;28(1 Suppl 1):20–4.PubMedGoogle Scholar
  18. 18.
    Van Cutsem E et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.PubMedGoogle Scholar
  19. 19.
    Topham C, Boni C, Navarro M, et al. Multicenter international randomized study of oxaliplatin/5FU/LV (FOLFOX) in stage II and III colon cancer (MOSAIC trial): final results. Eur J Cancer. 2003;1 Suppl 5:S324–5. abstract 1085.Google Scholar
  20. 20.
    Andre T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.PubMedGoogle Scholar
  21. 21.
    Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.PubMedGoogle Scholar
  22. 22.
    O’Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol. 2009;27(19):3082–4.PubMedGoogle Scholar
  23. 23.
    Allegra CJ et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27(20):3385–90.PubMedGoogle Scholar
  24. 24.
    Carrato A. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res. 2008;2(4 Suppl):S42–6.PubMedGoogle Scholar
  25. 25.
    Krook JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–15.PubMedGoogle Scholar
  26. 26.
    Willett C et al. Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys. 1984;10(5):645–51.PubMedGoogle Scholar
  27. 27.
    Gunderson LL, Sosin H, Levitt S. Extrapelvic colon – areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1985;11(4):731–41.PubMedGoogle Scholar
  28. 28.
    Willett CG et al. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol. 1993;11(6):1112–7.PubMedGoogle Scholar
  29. 29.
    Schild SE et al. The treatment of locally advanced colon cancer. Int J Radiat Oncol Biol Phys. 1997;37(1):51–8.PubMedGoogle Scholar
  30. 30.
    Amos EH et al. Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol. 1996;3(5):431–6.PubMedGoogle Scholar
  31. 31.
    Martenson J, Willett C, Sargent D, et al. A phase III study of adjuvant radiation therapy (RT), 5-fluorouracil (5-FU), and levamisole (LEV) vs. 5-FU and LEV in selected patients with resected, high-risk colon cancer: initial results of INT 0130. Proc Am Soc Clin Oncol. 1999;18:235. abstract.Google Scholar
  32. 32.
    Gunderson LL et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002;54(2):386–96.PubMedGoogle Scholar
  33. 33.
    Schultz I et al. Longterm results and functional outcome after Ripstein rectopexy. Dis Colon Rectum. 2000;43(1):35–43.PubMedGoogle Scholar
  34. 34.
    Shibata D et al. Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol. 1999;6(1):33–7.PubMedGoogle Scholar
  35. 35.
    Paty P et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236:522–9.PubMedGoogle Scholar
  36. 36.
    Russell A et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. Int J Radiat Oncol Biol Phys. 2000;46:313–22.PubMedGoogle Scholar
  37. 37.
    Chakravarti A et al. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg. 1999;230:49–54.PubMedGoogle Scholar
  38. 38.
    Mendenhall W et al. Local excision and postoperative radiation therapy for rectal adenocarcinoma. Int J Cancer. 2001;96:89–96.PubMedGoogle Scholar
  39. 39.
    Hight D et al. Linear cauterization for the treatment of rectal prolapse in infants and children. Surg Gynecol Obstet. 1982;154:400–2.PubMedGoogle Scholar
  40. 40.
    Gimbel M, Paty P. A current perspective on local excision of rectal cancer. Clin Colorectal Cancer. 2004;4(1):26–35.PubMedGoogle Scholar
  41. 41.
    Ota DM, Nelson H. Local excision of rectal cancer revisited: ACOSOG protocol Z6041. Ann Surg Oncol. 2007;14(2):271.PubMedGoogle Scholar
  42. 42.
    Bullard Dunn K. Adjuvant and neoadjuvant therapy for rectal cancer. Access MedicineUpdate, Schwartz’s principles of surgery. 8th ed. doi: http://www.accessmedicine.com/updatesContent.aspx?aid=1000693.
  43. 43.
    Heald R, Husband E, Ryall R. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.PubMedGoogle Scholar
  44. 44.
    Heald R et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998;133:894–9.PubMedGoogle Scholar
  45. 45.
    Kapeteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.Google Scholar
  46. 46.
    Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Swedish Rectal Cancer Trial. Br J Surg. 1993;80(10):1333–6.Google Scholar
  47. 47.
    Camma C et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.PubMedGoogle Scholar
  48. 48.
    Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304.Google Scholar
  49. 49.
    Glimelius B et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 2003;42(5–6):476–92.PubMedGoogle Scholar
  50. 50.
    Moriya Y et al. Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum. 1989;32(4):307–15.PubMedGoogle Scholar
  51. 51.
    Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J Surg. 1992;16(5):848–57.PubMedGoogle Scholar
  52. 52.
    Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg. 1992;127(12):1396–401. discussion 1402.PubMedGoogle Scholar
  53. 53.
    Wibe A et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89(3):327–34.PubMedGoogle Scholar
  54. 54.
    Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br J Surg. 1999;86(3):379–84.PubMedGoogle Scholar
  55. 55.
    Martling AL et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356(9224):93–6.PubMedGoogle Scholar
  56. 56.
    Swedish Rectal Cancer Register. http://www.SOS.se/mars/kvaflik.htm.
  57. 57.
    Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedGoogle Scholar
  58. 58.
    Bosset JF et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.PubMedGoogle Scholar
  59. 59.
    Collette L et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25(28):4379–86.PubMedGoogle Scholar
  60. 60.
    Garcia-Aguilar J et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46(3):298–304.PubMedGoogle Scholar
  61. 61.
    Chen E et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys. 1994;30:169–75.PubMedGoogle Scholar
  62. 62.
    Minsky B et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 1992;10(1):79–84.PubMedGoogle Scholar
  63. 63.
    Minsky B et al. Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys. 1995;31:553–9.PubMedGoogle Scholar
  64. 64.
    Minsky B et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys. 1997;37:289–95.PubMedGoogle Scholar
  65. 65.
    Rouanet P et al. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results. Ann Surg. 1995;221(1):67–73.PubMedGoogle Scholar
  66. 66.
    Janjan N et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999;44(5):1027–38.PubMedGoogle Scholar
  67. 67.
    Kaminsky-Forrett M et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3–T4 rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:935–41.PubMedGoogle Scholar
  68. 68.
    Chan A et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int J Radiat Oncol Biol Phys. 2000;48:843–56.PubMedGoogle Scholar
  69. 69.
    Theodoropoulos G et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002;45:895–903.PubMedGoogle Scholar
  70. 70.
    Moore H et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47(3):279–86.PubMedGoogle Scholar
  71. 71.
    Bullard KM et al. Primary perineal wound closure after APR: doomed to fail? Dis Colon Rectum. 2005;48(3):438–443.Google Scholar
  72. 72.
    Nissan A et al. Abdominoperineal resection for rectal cancer at a specialty center. Dis Colon Rectum. 2001;44(1):27–36.PubMedGoogle Scholar
  73. 73.
    Luna-Perez P et al. Morbidity and mortality following abdominoperineal resection for low rectal adenocarcinoma. Rev Invest Clin. 2001;53(5):388–95.PubMedGoogle Scholar
  74. 74.
    Papacontantinou H et al. Salvage APR after failed Nigro protocol: modest success, major morbidity. Dis Colon Rectum. 2003;46(5):A63.Google Scholar
  75. 75.
    Janjan N et al. Locally advanced rectal cancer: surgical complications after infusional chemotherapy and radiation therapy. Radioology. 1998;206(1):131–6.Google Scholar
  76. 76.
    Temple L, Wong W, Minsky B. The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Rad Oncol. 2003;13(4):469–77.Google Scholar
  77. 77.
    Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990;211(2):187–95.PubMedGoogle Scholar
  78. 78.
    Sauer R et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German rectal cancer trial. Colorectal Dis. 2003;5:406–15.PubMedGoogle Scholar
  79. 79.
    Sauer R et al. Preoperative versus postoperative chemoradiation for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedGoogle Scholar
  80. 80.
    Fakih MG et al. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2008;72(3):650–7.PubMedGoogle Scholar
  81. 81.
    Rodel C et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25(1):110–7.PubMedGoogle Scholar
  82. 82.
    Bamberger P, Otchy D. Ileoanal pouch in the active duty population: effect on military career. Dis Colon Rectum. 1997;40(1):60–6.PubMedGoogle Scholar
  83. 83.
    Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy for resectable rectal cancer. N Engl J Med. 1997;336:980–7.Google Scholar
  84. 84.
    Habr-Gama A et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41(9):1087–96.PubMedGoogle Scholar
  85. 85.
    Stein D et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal cancer. Dis Colon Rectum. 2003;46(4):448–53.PubMedGoogle Scholar
  86. 86.
    Frigell A et al. Quality of life of patients treated with abdominoperineal resection or anterior resection for rectal carcinoma. Ann Chir Gynaecol. 1990;79(1):26–30.PubMedGoogle Scholar
  87. 87.
    Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001;85(10):1437–43.PubMedGoogle Scholar
  88. 88.
    Pahlman L, Glimelius B, Enblad P. Clinical characteristics and their relation to surgical curability in adenocarcinoma of the rectum and rectosigmoid. A population-based study on 279 consecutive patients. Acta Chir Scand. 1985;151(8):685–93.PubMedGoogle Scholar
  89. 89.
    Moertel CG et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.PubMedGoogle Scholar
  90. 90.
    Overgaard M, Berthelsen K, Dahlmark M, Gadeberg CG, van der Maase H, Overgaard J, et al. A randomized trial of radiotherapy alone or combined with 5-FU in the treatment of locally advanced colorectal carcinoma. ECCO 5, meeting abstract;1989:0-0626.Google Scholar
  91. 91.
    Wassif SB. The role of pre-operative adjuvant therapy in the management of borderline operability rectal cancer. Clin Radiol. 1982;33(3):353–8.PubMedGoogle Scholar
  92. 92.
    Frykholm GJ, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys. 2001;50(2):427–34.PubMedGoogle Scholar
  93. 93.
    Janjan NA et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999;51(2):153–60.PubMedGoogle Scholar
  94. 94.
    Bouzourene H et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94(4):1121–30.PubMedGoogle Scholar
  95. 95.
    Mathis KL et al. Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg. 2008;248(4):592–8.PubMedGoogle Scholar
  96. 96.
    Glynne-Jones R, Sebag-Montefiore D. Chemoradiation schedules – what radiotherapy? Eur J Cancer. 2002;38(2):258–69.PubMedGoogle Scholar
  97. 97.
    Valentini V et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys. 1999;45(5):1175–84.PubMedGoogle Scholar
  98. 98.
    Grann A et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum. 1997;40(5):515–22.PubMedGoogle Scholar
  99. 99.
    Hyams DM et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum. 1997;40(2):131–9.PubMedGoogle Scholar
  100. 100.
    Rouanet P et al. Restorative and nonrestorative surgery for low rectal cancer after high-dose radiation: long-term oncologic and functional results. Dis Colon Rectum. 2002;45(3):305–13. discussion 313–5.PubMedGoogle Scholar
  101. 101.
    Mohiuddin M et al. High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum. Int J Radiat Oncol Biol Phys. 1998;40(3):569–74.PubMedGoogle Scholar
  102. 102.
    Moore HG et al. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol. 2003;10(1):80–5.PubMedGoogle Scholar
  103. 103.
    Karnjia ND, Schache DJ, North WR, Heald RJ. “Close shave” in anterior resection. Br J Surg. 1990;63:673–7.Google Scholar
  104. 104.
    Francois Y et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.PubMedGoogle Scholar
  105. 105.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15–24.PubMedGoogle Scholar
  106. 106.
    Hanna Jr MG et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001;19(17–19):2576.PubMedGoogle Scholar
  107. 107.
    Hoover Jr HC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–9.PubMedGoogle Scholar
  108. 108.
    Harris JE et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18(1):148–57.PubMedGoogle Scholar
  109. 109.
    Vermorken JB et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353(9150):345–50.PubMedGoogle Scholar
  110. 110.
    Fallik D et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63(18):5738–44.PubMedGoogle Scholar
  111. 111.
    Barratt PL et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360(9343):1381–91.PubMedGoogle Scholar
  112. 112.
    Des Guetz G et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890–6.PubMedGoogle Scholar
  113. 113.
    Gusella M et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009;100(10):1549–57.PubMedGoogle Scholar
  114. 114.
    Afzal S et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009;20(10):1660–6.PubMedGoogle Scholar
  115. 115.
    Khambata-Ford S et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–7.PubMedGoogle Scholar
  116. 116.
    Freeman DJ et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer. 2008;7(3):184–90.PubMedGoogle Scholar
  117. 117.
    Amado RG et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Kelli Bullard Dunn
    • 1
  • Judith L. Trudel
    • 2
  1. 1.Roswell Park Cancer Institute and the University of Buffalo, State University of New YorkBuffaloUSA
  2. 2.Department of SurgeryUniversity of MinnesotaSt. PaulUSA

Personalised recommendations